RHEUMATIC FEVER
Rheumatic fever usually occurs in children 5 to 15 years of age. It is caused by group A beta hemolytic streptococcal pharyngitis that occurs one to three weeks prior to the clinical manifestations of rheumatic fever. It is believed that an immune response to the Streptococcus is responsible for the disease. Males and females are equally affected. It is more common in patients of lower socioeconomic level. The incidence of rheumatic fever in the United States has declined in recent years.
Aschoff nodules in the myocardium are the characteristic pathological feature of rheumatic fever. The most serious manifestation of rheumatic fever is a pancarditis that may involve the endocardium, myocardium, and pericardium. Usually the mitral valve, less frequently the aortic, and even less frequently the tricuspid valve are involved. Pulmonic valve involvement is extremely rare. Valvulitis is recognized by a new insufficiency murmur. Aortic and mitral stenosis murmurs are not heard acutely. Myocarditis may present with heart failure. Pericarditis may produce a friction rub, and the PR interval may prolong. Because of the difficulty in diagnosing rheumatic fever, guidelines (modified Jones criteria) for establishing the diagnosis were developed (Table 5-4).
Penicillin should be administered to eradicate streptococcal infection. Salicylates are effective rapidly ior treating fever and arthritis but probably have no effect on carditis. The usefulness of steroids is unproven. Congestive heart failure is treated traditionally.
The relatively high recurrence rate of rheumatic fever after streptococcal infection continues for at least 5 to 10 years after the initial infection; therefore, rheumatic fever prophylaxis should be discontinued only in adults 5 to 10 years after the acute episode and only then if the risk of the streptococcal infection is low. Adults working with school-age children, those in the military service, those exposed to large numbers of people, and those in the medical or allied health professions should receive prophylaxis indefinitely. Patients who have a significant degree of rheumatic heart disease or a history of repeated occurrences should have prophylaxis indefinitely. The recommended regimen for prophylaxis is 1.2 million units of benzathine penicillin monthly. Oral penicillin, erythromycin, or sulfadiazine can be used but because of noncompliance are somewhat less effective than the parenteral regimen.
- Magnetic Resonance Imaging (MRI)
- AORTIC DISEASE - AORTIC ANEURYSMS
- Upper GI Bleeding
- Urinalysis, Renal ‘Tubular Function, and Urine Flow Rate
- Incidence
- Reduction in GFR
- Outcomes of Dialysis
- DEFINITION
- MULTIVALVULAR DISEASE
- GENERAL MANAGEMENT OF MYOCARDIAL INFARCTION
- Hepatocellular Carcinoma
- Renal Tumors
- DROWNING AND NEAR-DROWNING
- Blood Chemistries
- NAUSEA AND VOMITING
- ACUTE RENAL INSUFFICIENCY
- ETIOLOGY OF GASTROINTESTINAL BLEEDING
- Visceral Angiography
- Clinical Manifestations
- PULMONARY GAS EXCHANGE
- PATHOPHYSIOLOGY OF AIRWAY OBSTRUCTION
- CARDIOMYOPATHY
- Nephrogenic Diabetes Insipidus (NDI)
- Sigmoidoscopy and Colonoscopy
- Radionuclide Imaging
- Alterations in Drug Doses in Patients with Renal Failure
- MICROSCOPIC ANATOMY
- NORMAL GASTRIC PHYSIOLOGY
- Diagnosis
- Treatment and Prognosis
- MOTOR DISORDERS OF THE ESOPHAGUS
- MYOCARDIAL METABOLISM
- Clinical Manifestations
- SCREENING TESTS OF HEPATOBILIARY DISEASE
- RESPIRATORY SENSORS